Investors of Sana Biotechnology, Inc. Urged to Act in Class Action Lawsuit by Levi & Korsinsky
Sana Biotechnology, Inc. Class Action: Important Information for Investors
On May 2, 2025, Levi & Korsinsky, LLP announced to investors of Sana Biotechnology, Inc. (NASDAQ: SANA) the initiation of a class action lawsuit concerning allegations of significant securities fraud. This legal action aims to recover losses incurred by individuals directly affected by misleading public statements made by the company during the period between March 17, 2023, and November 4, 2024.
Background of the Case
The lawsuit centers on accusations that the management of Sana Biotechnology made false assertions, leading investors to believe in the firm's financial stability and the viability of its product pipeline. Specifically, it is alleged that Sana was facing a substantial risk of having inadequate funds to continue its operations and develop its product candidates. Notably, the company's oncology candidates, SC291, SC379, and SG299, were reportedly less promising than previously communicated.
According to the claims filed, it became apparent that in order to economize cash and prioritize more promising candidates, the company was likely to either reduce funding for or cease development on these products, potentially resulting in job cuts. Such decisions would inherently contradict previous statements made by Sana's executives regarding the company's financial health and operational capabilities.
Legal Proceedings and Next Steps
Investors impacted by these circumstances have a critical deadline. Those wishing to participate in the legal proceedings must request to be appointed as a lead plaintiff by May 20, 2025. It is essential to note that participating as a class member does not necessitate serving as a lead plaintiff; eligible investors may still benefit from any potential recoveries without this role.
Levi & Korsinsky encourages affected investors to reach out promptly for more information. They can follow the link provided on their official press release to access further details about the lawsuit and the steps required for participation: Sana Biotechnology Inc. Lawsuit Submission Form.
No Costs Involved
Participation in the class action lawsuit comes at no cost to affected shareholders. Levi & Korsinsky emphasizes that if investors are part of the class, they may be eligible for compensation without incurring any legal fees or out-of-pocket expenses. This opportunity allows shareholders to seek justice without financial barriers.
Why Trust Levi & Korsinsky?
With two decades of experience in navigating complex securities litigation, Levi & Korsinsky has built a robust reputation among investors. Their track record showcases the recovery of hundreds of millions of dollars for shareholders in previous cases. The firm has consistently been recognized for its performance in securities class actions, being listed in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years as one of the leading litigation firms in the United States.
Contact Information
For further inquiries related to this case, shareholders can contact:
- - Joseph E. Levi, Esq.
- - Ed Korsinsky, Esq.
Email: jlevi@zlk.com
Phone: (212) 363-7500
Website: www.zlk.com
Now is the time for affected investors of Sana Biotechnology, Inc. to take action and ensure their voices are heard. The legal landscape can be complex, but navigating it with experienced counsel is paramount for financial recovery.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.